Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ: PACB) announced it will hold its quarterly conference call to discuss the fourth quarter and full year 2021 financial results on February 15, 2022, at 4:30 pm ET. This call will be accessible via a live webcast on the Pacific Biosciences website. The company aims to provide insights into its financial performance and future outlook, reflecting its commitment to empowering life scientists through advanced sequencing technologies.
PacBio (NASDAQ: PACB) announced on January 14, 2022, that its Compensation Committee granted non-qualified stock options for 80,000 shares and restricted stock units (RSUs) for 40,000 shares to a new employee. This action is part of the 2020 Inducement Equity Incentive Plan, aimed at attracting talent. The options have an exercise price of $16.58, equal to the stock's closing price on January 10, 2022. Vesting for options and RSUs will occur over four years, aligning employee incentives with long-term company performance.
PacBio has appointed Lara Toerien, Ph.D., as Vice President and General Manager for the Americas region, aiming to enhance its commercial growth strategy. Toerien brings over 25 years of experience, previously serving as Senior Regional Sales Director at Illumina. She will focus on expanding the adoption of PacBio’s long-read sequencing technology across various fields, including infectious diseases and genomics. PacBio’s innovative SMRT Sequencing technology is well-regarded in the scientific community, facilitating comprehensive genetic analysis globally.
PacBio (NASDAQ: PACB) has announced a new collaboration with Berry Genomics to develop a desktop long read sequencing platform for the clinical market in China. Under the agreement, Berry Genomics will purchase at least 50 systems upon meeting product requirements. This partnership aims to expand the accessibility of PacBio's HiFi sequencing technology in Chinese laboratories, boosting offerings in the perinatal and carrier testing market. Building on a successful 2019 agreement, this initiative is expected to enhance the utilization of long read sequencing in clinical settings.
PacBio (NASDAQ: PACB) announces collaboration with Genomics England to explore the effectiveness of HiFi sequencing technology in identifying genetic variants in unexplained rare disease cases. This project will re-sequence samples from the 100,000 Genomes Project, which previously used short-read sequencing. The collaboration aims to demonstrate operational and clinical benefits of long-read sequencing, potentially uncovering additional genomic mutations. Insights from this research may lead to new therapeutic options for patients.
PacBio (NASDAQ: PACB) announced a collaboration with Google to enhance its HiFi Sequencing technology using Google's machine learning tools. This partnership aims to improve variant calling accuracy and maximize insights from PacBio's sequencing data. Previous research indicated that Google's DeepConsensus tool could potentially boost HiFi read accuracy by up to 27%. The collaboration is expected to facilitate advancements in applications like whole genome sequencing. Financial terms of the agreement were not disclosed.
PacBio (NASDAQ: PACB) announced preliminary revenue of $36.0 million for Q4 2021, marking a 33% increase from Q4 2020. Full-year 2021 revenue is expected to reach $130.5 million, a 65% growth from 2020. The company installed a record 48 Sequel II/IIe systems in Q4, increasing its total to 374 units. New sequencing kits are set for launch in H1 2022, improving efficiency and reducing sample input. The company plans to present at the 2022 JP Morgan Healthcare Conference on January 13. Note that actual results may differ from preliminary estimates.
PacBio announced the expansion of whole genome sequencing capacity at Radboud University Medical Center, increasing throughput for the SOLVE-RD program. This enhancement utilizes the PacBio Sequel IIe Systems, improving the identification of genetic variants in rare diseases. Notably, over 80% of rare disease cases are genetic, with many remaining unsolved. The system's precision is vital for detecting large variants missed by traditional methods. The program aims to sequence over 500 HiFi genomes by the end of 2022, contributing significantly to advancements in rare disease diagnostics.
PacBio announced a collaboration with Azenta Life Sciences to enhance its HiFi sequencing technology, aiming to improve genomic research capabilities globally. This partnership allows Azenta to utilize PacBio's Sequel IIe devices, expanding their genomic services to pharmaceuticals, biotechnology, and academic sectors. Azenta's strategic investment signifies a commitment to advancing research and delivering insights faster, supported by over 20 years in DNA and RNA sequencing. CEO Christian Henry emphasized the potential to redefine genomics and contribute to global health advancements.
PacBio partners with the Care4Rare Canada Consortium to explore unexplained rare disease cases using its high-resolution genome technology. The collaboration aims to improve diagnostic capabilities for rare diseases, impacting around one million Canadians, a significant portion of whom face severe health challenges. PacBio's HiFi long-read sequencing will be used to analyze samples previously sequenced by short-read technology. The goal is to enhance the understanding of rare diseases and increase diagnostic capacity, ultimately advancing patient care in Canada.